This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

DaVita-Brasnefro deal approved with remedies in Brazil

By Maria Júlia Baumert ( April 23, 2025, 22:37 GMT | Insight) -- DaVita's acquisition of Brasnefro — and indirectly, all its affiliates — was approved with conditions by the Brazilian competition authority Tribunal today after a blocking recommendation from its Superintendence. The Tribunal's green light is contingent on the signing of a confidential settlement agreement (ACC) which includes a mandatory divestiture plan aimed at addressing competition concerns.The acquisition of Brasnefro, a division of Fresenius Medical Care — and indirectly, all its affiliates — by DaVita, a major provider of kidney dialysis services, was approved with conditions by the Brazilian competition authority's Tribunal today after a blocking recommendation from its Superintendence....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login